Filing Details
Moleculin Biotech, Inc. (NASDAQ:MBRX) filed a Form 8-K with the Securities and Exchange Commission on August 14, 2026, disclosing a material event.
8k filedNASDAQ:MBRX
Moleculin Biotech, Inc. (MBRX) Reports Material Event to SEC
Moleculin Biotech, Inc. (NASDAQ:MBRX) filed a Form 8-K with the Securities and Exchange Commission on August 14, 2026, disclosing a material event.
At publication ·
What changed
Moleculin Biotech, Inc. (NASDAQ:MBRX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Moleculin Biotech, Inc. (NASDAQ: MBRX) filed a Form 8-K with the SEC on August 14, 2026, disclosing a material event that shareholders should be aware of.
- The company's stock trades at $0.61 per share with a market capitalization of $6.0 million.
- The article does not specify the nature of the material event disclosed in the 8-K filing, such as leadership changes, agreements, acquisitions, or financial guidance changes.
Market Context
Moleculin Biotech, Inc.'s stock currently trades at $0.61 with a market capitalization of $6.0M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Moleculin Biotech, Inc.'s stock.
All SEC filings for Moleculin Biotech, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View MBRX Stock Page
Frequently Asked Questions
Where can I read MBRX's SEC filings?
Browse all filings on our MBRX SEC filings page.
What types of SEC filings does Moleculin Biotech, Inc. file?
Public companies like Moleculin Biotech, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.